BD Molecular Diagnostics

Introducing the NEW BD MAX™ CT/GC/TV

  • Designed to address the 3 most prevalent non-viral sexually transmitted infections (STIs) in a single assay — Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis (CT/GC/TV)
  • Strong solutions to provide quality patient care and to support clinical decision accuracy and patient management
  • Versatility — fully integrated on the BD MAX™ System

Learn more about Elevating the Standard of Care for STIs

Why Change?
The consequences of CT, GC, and TV can be serious; TV is the most common curable STI worldwide. Annually in the United States, millions of new infections are estimated to occur, an amount greater than combined new cases of chlamydia, gonorrhea, and syphilis. Serious adverse reproductive health outcomes, including pregnancy complications, pelvic inflammatory disease, and an increased risk of HIV acquisition, have been linked to TV infection.4

3-5 times more vaginalis infections than

Why Now?
Hospitals and laboratories are faced with increasing challenges in managing workload and patient needs. Staggering cost to the US healthcare system caused by the growing number of new infections demands action in the way we test for CT/GC/TV. The high incidence and overall prevalence of STIs in the general population suggest that many Americans are at substantial risk of exposure to STIs.3

STD Estimated Numbers


Overall Performance

Why BD?
The right treatment starts with the right test. BD MAX CT/GC/TV tests for the Top 3 most prevalent non-viral STIs at 1 time, every time, from 1 patient collection. Accurate, reliable results provide clinicians with the full picture, enhancing quality patient care.

BD also offers the following systems for the detection of CT/GC: BD Viper™ System with XTR Technology, BD Viper™ LT System & BD ProbeTec™ System


References: 1. Baron EJ et al. Clin Infect Dis. 2013;57(4):e22-e121. 2. Van Der Pol B et al. Chlamydia, gonorrhea and trichomonas combined testing using the BD MAX™ CT/GC/TV assay using genitourinary specimen types [published online ahead of print October 26, 2016]. J Clin Microbiol. doi: 10.1128/JCM.01766-16. 3. Centers for Disease Control and Prevention. Accessed September 19, 2016. 4. Coleman JS et al. Obstet Gynecol Surv. 2013;68:43-50. 5. Centers for Disease Control and Prevention. Accessed September 20, 2016. 6. Centers for Disease Control and Prevention. Accessed September 20, 2016. 7. BD MAX CT/GC/TV Package Insert.